Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

• Sponsor: GemVax & Kael (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04032067
• Collaborator: (none)
• Enrollment: 423
• Locations: 23
• Arms: 3
• Actual Duration (Months): 28.6
• Patients Per Site: 18.4
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for Benign prostate hyperplasia(BPH). The investigational drug, GV1001, was first developed as a cancer vaccine for use as active immunotherapy of cancer forms expressing telomerase (eg, pancreatic cancer, prostate cancer, etc.). Subsequently, it was found that GV1001 showed efficacy in alleviating BPH symptoms during in vivo studies by reducing the size of the prostate gland. Based on the result, the effectiveness of GV1001 as a treatment for BPH has been assessed in experimental animals that are designed to develop BPH.

It is considered that GV1001 acts to alleviate BPH and the results obtained from previous phase II study indicate that GV1001 may provide potential beneficial effects in BPH patients.

So this study is to verify the efficacy and safety of GV1001 on BPH population, large-scale clinical study than phase II.

Condition or Disease	Intervention/Treatment	Phase
Benign Prostatic Hyperplasia (BPH)	Drug: GV1001 placebo; Drug: Proscar placebo	Phase 3

Detailed Description

This was a multi-center, randomized, Double-blind, Active-controlled, parallel design, Phase 3 study in patients with BPH. The study consisted of a Screening period, a 4-weeks Run-in/Washout period, a 24-week Treatment period, an Evaluation and Close-out Visit at Week 24.

There are a total of 3 groups in this study, which contained 2 study groups (GV1001) and 1 placebo group (0.9% normal saline). Approximately 417 patients are planned to be randomly assigned into the study in a 1:1:1 ratio. All patients are randomized into 1 of 3 treatment groups to ensure completion of patients.

The Screening period have a time period of 4 weeks before the beginning of Run-in/Washout period. Eligible patients entered into a 4-week Run-in/Washout period and receive placebo treatment, which will be completed before randomization on Week 0. All randomized patients will receive the investigational drug or a placebo via intradermal injection 12 times with a 2-week interval at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. Efficacy evaluation will be conducted at Weeks 4, 8, 12, 16, 20 and 24, and safety evaluation will be conducted throughout the 24-weeks period.

Study Design

• Study Type: Interventional
• Actual Enrollment: 423 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
• Actual Study Start Date: Oct 30, 2019
• Actual Primary Completion Date: Mar 17, 2022
• Actual Study Completion Date: Mar 17, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Control Group GV1001-Placebo ID injection administered every 2 weeks through Week 24 + Proscar PO administered once a day through Week 24	Drug: GV1001 placebo; 0.9 % Normal Saline; Other Names: Normal Saline
Experimental: Study Group 1 GV1001 0.56 mg ID injection administered every 2 weeks through Week 24 + Proscar-placebo PO administered once a day through Week 24	Drug: Proscar placebo; PO; Other Names: Finasteride
Experimental: Study Group 2 GV1001 1.12 mg ID injection administered every 2 weeks through Week 24 + Proscar-placebo PO administered once a day through Week 24	Drug: Proscar placebo; PO; Other Names: Finasteride

Outcome Measures

Primary Outcome Measures

1. Change in International Prostate Symptom Score(IPSS) [Week 24]

   The amount of change from International Prostate Symptom Score(IPSS )compared to the baseline. The measures of the 7 items evaluating symptoms is evaluated from 0 to 5 for each item, the total coverage range is from 0 (no symptoms) to 35 (most severe symptoms). And the quality of life assessment is assessed from 0 (very satisfactory) to 6 (very unsatisfactory).

Secondary Outcome Measures

1. Change in International Prostate Symptom Score(IPSS) [Weeks 4, 8, 12, 16 and 20]

   The amount of change from International Prostate Symptom Score(IPSS )compared to the baseline. The measures of the 7 items evaluating symptoms is evaluated from 0 to 5 for each item, the total coverage range is from 0 (no symptoms) to 35 (most severe symptoms). And the quality of life assessment is assessed from 0 (very satisfactory) to 6 (very unsatisfactory).

2. Change in voiding score of International Prostate Symptom Score(IPSS) [Weeks 4, 8, 12, 16, 20 and 24]

   The amount of change from voiding score of IPSS compared to the baseline. The voiding score is measured as the sum of the evaluation scores of items 1, 3, 5 and 6 of the seven symptom scores of the IPSS.

3. Change in Prostatic Volume(PV) [Weeks 12 and 24]

   The amount of change from Prostatic Volume(PV) compared to the baseline.

4. Change in Maximum(peak) Urinary Flow Rate [Weeks 12 and 24]

   The amount of change from Maximum(peak) Urinary Flow Rate compared to the baseline

5. Change in Prostate-specific Antigen (PSA) [Weeks 12 and 24]

   The amount of change from Prostate-specific Antigen (PSA) compared to the baseline

6. Change in Residual Urine Volume [Weeks 12 and 24]

   The amount of change from Residual Urine Volume compared to the baseline

7. Change in Hormones (Testosterone, DHT) [Weeks 4, 8, 12, 16, 20 and 24]

   The amount of change from Hormones (Testosterone, DHT) compared to the baseline

8. Change in International Index of Erectile Function (IIEF) [Weeks 4, 8, 12, 16, 20 and 24]

   The amount of change from International Index of Erectile Function (IIEF) compared to the baseline

9. rate of incidence of Acute urinary tract(AUR) [Every 2 weeks After screening visit up to 24 week]

   The rate of incidence of Acute urinary tract(AUR), meaning clinical progression of prostate hypertrophy

10. Ratio of prostate surgery and minimally invasive (non-surgical) procedure [Every 2 weeks After screening visit up to 24 week]

    The ratio of prostate surgery and minimally invasive (non-surgical) procedure, meaning clinical progression of prostate hypertrophy

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years and Older
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. A male at 50 years of age and older

2. Clinical signs and symptoms of benign prostatic hyperplasia

3. A volume of prostate gland (TRUS) > 30 cc

4. Moderate to severe lower urinary tract symptoms with IPSS ≥ 13

5. 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL

6. PSA level < 10 ng/mL (however, if 4 ng/mL < PSA < 10 ng/mL, a person with a biopsy result, confirming that he does not have prostate cancer)

7. Residual urine volume ≤ 200 Ml

8. Consent not to participate in other clinical trials as a subject during this clinical trial period.

9. Consent of patient and patient's partner a. Patient

• Consent to avoid pregnancy by using condoms for 90 days after the end of study participation period and treatment. (Not applied if the patient had vasectomy.)

1. Patient's partner (Consent should be obtained before visit 4, when necessary.)

• Consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized.

Exclusion Criteria:

1. Hypersensitivity reactions to ingredients of this drug.

2. Taking drugs that affect the results of clinical trials. ex) 5-alpha reductase inhibitors, drugs similar to LHRH, alpha blockers, alpha-beta blockers, anticholinergics, antidiuretic hormones, diuretics, PDE-5 inhibitors, beta-3 adrenoceptor antagonists, steroids, immune suppressants, saw palmetto, etc.

3. Taking drugs of an unapproved study drug in the past or the study drug for this clinical trial

4. Diagnosis with prostate cancer in the past or at present

5. Diagnosis by an investigator to have an influence to an evaluation on urine flow symptoms due to other previous or current diseases besides benign prostatic hyperplasia

6. Surgeries or radiation therapies for prostate gland, bladder or pelvis, or who had invasive treatments for benign prostatic hyperplasia

7. Severe medical condition which may be cause problem to conduct the clinical trial (e.g., chronic heart failure (CHF), difficult-to-control diabetes (HbA1c > 7%), mental disorder, drug, or alcohol abuse, etc.)

8. Moderate to severe liver hypofunction and severe kidney hypofunction (less than 30 mL/min of creatinine clearance)

9. Any other subjects who are considered to be ineligible for this study by an investigator

[Inclusion Criteria for Randomization]

1. Clinical signs and symptoms of benign prostatic hyperplasia

2. Volume of prostate gland (TRUS) > 30 cc *

3. moderate to severe lower urinary tract symptoms with IPSS ≥ 13

4. 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL

5. Residual urine volume ≤ 200 mL

6. Patient's partner (Consent should be obtained before visit 4, when necessary.) - Consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized.

(* In case that additional TRUS examination has been performed after screening, a decision should be made based on the latest result.)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hanyang University Guri Hospital	Guri-si	Gyeonggi-do	Korea, Republic of
2	Seoul National University Bundang Hospital	Seongnam-si	Gyeonggi-do	Korea, Republic of
3	Dongguk University Gyeongju Hospital	Gyeongju	Gyeongsangbuk-do	Korea, Republic of
4	Hallym University Medical Center	Anyang		Korea, Republic of
5	Inje University Busan Paik Hospital	Busan		Korea, Republic of
6	Samsung Changwon Medical Center	Changwon		Korea, Republic of
7	Soonchunhyang University Hospital	Cheonan		Korea, Republic of
8	Chungbuk National University Hospital	Chungbuk		Korea, Republic of
9	Chonnam National University Hospital	Chungnam		Korea, Republic of
10	Daegu Catholic University Medical Center	Daegu		Korea, Republic of
11	Keimyung University Dongsan Medical Center	Daegu		Korea, Republic of
12	Kyungpook National University Chilgok Hospital	Daegu		Korea, Republic of
13	Yeungnam University Medical Center	Daegu		Korea, Republic of
14	Dongguk University Ilsan Hospital	Ilsan		Korea, Republic of
15	Jeonbuk National University Hospital	Jeonju		Korea, Republic of
16	Asan Medical Center	Seoul		Korea, Republic of
17	Chung-ang University Hospital	Seoul		Korea, Republic of
18	Eulji General Hospital	Seoul		Korea, Republic of
19	Korea University Guro Hospital	Seoul		Korea, Republic of
20	Samsung Medical Center	Seoul		Korea, Republic of
21	Severance Hospital	Seoul		Korea, Republic of
22	The Catholic University of Korea, Seoul ST. Mary's Hospital	Seoul		Korea, Republic of
23	Pusan National University Yangsan Hospital	Yangsan		Korea, Republic of

Sponsors and Collaborators

• GemVax & Kael

Investigators

• Study Chair: Kyung Seop Lee, Department of Urology, Dongguk University Gyeongju Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: GemVax & Kael
• ClinicalTrials.gov Identifier: NCT04032067
• Other Study ID Numbers: KG8/2019
• First Posted: Jul 25, 2019
• Last Update Posted: Aug 25, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by GemVax & Kael: Benign Prostatic Hyperplasia; GV1001
• Additional relevant MeSH terms: Prostatic Hyperplasia; Hyperplasia; Finasteride

Study Results

No Results Posted as of Aug 25, 2022